10-K: Premier Inc. Reports FY25 Revenue Decline Amid Strategic Shifts

Premier Inc. reported a significant decrease in net revenue and adjusted EBITDA for fiscal year 2025, driven by strategic divestitures and competitive market pressures, despite ongoing share repurchases.

Summary

• Net revenue decreased by $123.4 million, or 11%, to $1,012.6 million in fiscal year 2025 compared to $1,136.0 million in fiscal year 2024.
• Net income from continuing operations decreased to $72.7 million in fiscal year 2025 from $104.2 million in fiscal year 2024.
• Non-GAAP Adjusted EBITDA decreased by $135.9 million, or 35%, to $253.1 million in fiscal year 2025 from $388.9 million in fiscal year 2024.
• Supply Chain Services segment revenue decreased by $58.3 million, or 8%, primarily due to an 11% decrease in net administrative fees revenue driven by higher aggregate blended fee share paid to members.
• Performance Services segment revenue decreased by $65.0 million, or 15%, mainly due to lower Contigo Health revenue, contract expirations, and fewer new consulting engagements.
• A pre-tax goodwill impairment charge of $126.8 million was recognized in the second quarter of fiscal year 2025 related to the Informatics and Technology Services (ITS) reporting unit.
• The company completed $800.0 million in share repurchases under a $1.0 billion authorization, which expired on June 30, 2025.
• The S2S Global direct sourcing subsidiary was divested on October 1, 2024, for a 20% minority interest in Prestige Ameritech, resulting in a net impact of a $39.8 million loss associated with the divestiture, including a $52.6 million loss from discontinued operations.
• Contigo Health's wrap network business was sold on January 16, 2025, for $15.0 million, resulting in a $13.9 million gain.
• The company received $57.0 million in cash from the settlement of a shareholder derivative complaint in July 2024.
• Early termination payments to former limited partners related to the August 2020 Restructuring, totaling $102.7 million, were completed in the fourth quarter of fiscal year 2025.

Sentiment

Score: 3

Explanation: The company experienced significant declines in key financial metrics (net revenue, net income, Adjusted EBITDA) and recorded a substantial goodwill impairment charge. The shift to a net working capital deficit and increased interest expense indicate financial strain. While strategic divestitures and share repurchases were completed, the overall performance for the fiscal year was weak, suggesting significant operational and market challenges.

Positives

• The company completed $800.0 million in share repurchases under its $1.0 billion Share Repurchase Authorization, demonstrating a commitment to returning capital to shareholders.
• A non-operating gain of $57.0 million was realized from the settlement of a shareholder derivative complaint.
• The sale of Contigo Health's wrap network business generated a gain of $13.9 million.
• Increased utilization and further penetration of GPO contracts by existing members partially offset the decline in Supply Chain Services revenue.
• Supply chain co-management fees increased by $9.5 million due to new engagements.
• Enterprise analytics license revenue increased by $4.7 million.
• Received a $17.6 million cash dividend from an unconsolidated affiliate.
• The company was recognized as the 'World's Most Ethical Company' for the 18th consecutive year and listed among 'America's Best Management Consulting Firms' by Forbes for 2024 and 2025.

Negatives

• Net revenue decreased by 11% ($123.4 million) in fiscal year 2025 compared to the prior year.
• Net income from continuing operations decreased by $31.5 million in fiscal year 2025.
• Non-GAAP Adjusted EBITDA saw a significant 35% decrease ($135.9 million) year-over-year.
• The Supply Chain Services segment experienced an 11% decrease in net administrative fees revenue due to increased aggregate blended fee share paid to members.
• The Performance Services segment's revenue declined by 15%, impacted by lower Contigo Health revenue, contract expirations, and fewer new consulting engagements.
• A substantial pre-tax goodwill impairment charge of $126.8 million was recorded for the Informatics and Technology Services (ITS) reporting unit.
• The company reported a net loss from discontinued operations of $41.9 million in fiscal year 2025, primarily due to a $53.0 million loss on the S2S Divestiture.
• Interest expense, net, increased significantly to $17.2 million in fiscal year 2025 from $0.7 million in fiscal year 2024, largely due to Credit Facility borrowings.
• Cash paid for operating expenses increased by $60.9 million, mainly due to performance-related compensation.
• Net working capital shifted from a surplus of $8.7 million at June 30, 2024, to a deficit of $324.8 million at June 30, 2025, primarily due to Credit Facility borrowings for stock repurchases.
• Increased bad debt expense was noted in operating expenses.

Risks

• Intense competition in both Supply Chain Services and Performance Services segments, including from large traditional GPOs, provider-owned GPOs, online retailers, and large IT/consulting firms.
• Competitive pressure to increase the share of administrative fees paid to members, which has already resulted in material increases and is expected to continue, particularly with upcoming GPO contract renewals.
• Consolidation in the healthcare industry could lead members to reduce reliance on the company, contract directly with suppliers, or negotiate increased revenue share obligations and fee reductions.
• Potential for delays in recognizing or increasing revenue if sales cycles or implementation periods for new products and services take longer than anticipated.
• Risk of GPO members reducing activity levels, terminating, or electing not to renew their contracts, especially as agreements extended in 2020 approach renewal (approximately 20% of gross administrative fees still need to be addressed, with the majority expected in fiscal year 2026).
• Markets for SaaS-based product subscriptions and licensed-based products and services may develop more slowly than expected, leading to volatility in revenue and growth rates.
• High dependency of members and other customers on payments from third-party healthcare payers (Medicare, Medicaid); reductions or changes in reimbursement could adversely affect demand for the company's products and services.
• Ability to maintain or enter into new strategic relationships with other companies, as these partners may pursue relationships with competitors or develop competing products.
• Failure to timely offer new and innovative products and services, including those incorporating artificial intelligence, could lead to a loss of competitiveness.
• Risks and expenses related to future acquisition opportunities and the integration of acquired businesses, including the potential for impairments (e.g., $126.8 million goodwill impairment in FY2025 for ITS reporting unit).
• Financial and operational risks associated with non-controlling investments in other businesses or joint ventures, particularly early-stage companies.
• Reliance on Internet infrastructure, bandwidth providers, data center providers, and internal systems; any failure or interruption could lead to litigation and negatively impact user relationships.
• Risk of data loss or corruption due to failures or errors in systems and service disruptions at data centers.
• Significant financial, operational, legal, and reputational consequences from cyber-attacks or other data security breaches.
• Restrictions on the use of, or ability to license, data, or failure to integrate third-party technologies could materially affect the business.
• Risks associated with the use of open source software, including potential litigation or requirements to offer products at no cost.
• Growing dependence on and need to invest in artificial intelligence (AI) technologies, with risks related to their emerging nature, evolving legal/regulatory frameworks, and potential for flawed or biased results.
• Inability to attract, hire, integrate, and retain key personnel in a competitive labor market could harm the business.
• Continued uncertain economic conditions, including inflation, tariffs, and recessionary fears, impairing forecasting ability and harming business operations.
• Financial and operational uncertainty due to global macroeconomic, geopolitical, and business conditions, including military conflicts and associated supply chain challenges.
• Adverse effects from global climate change or regulatory responses to such change, potentially increasing costs and supply chain volatility.
• Increased scrutiny and evolving expectations regarding ESG and DEI practices, which may impose additional costs or expose the company to new risks.
• Changes and uncertainty in the political, economic, or regulatory environment affecting healthcare organizations, including the Patient Protection and Affordable Care Act (ACA) and executive orders (e.g., 'One Big Beautiful Bill Act' reducing Medicaid expenditures).
• Compliance with complex federal and state laws and regulations governing financial relationships among healthcare providers (Anti-Kickback, False Claims Act, HIPAA, ERISA, antitrust laws, FDA regulation of software as medical devices).
• Potential for additional indirect tax liabilities, such as gross receipts and sales and use taxes, in certain jurisdictions.
• Changes in tax laws (e.g., 2025 U.S. Tax Act) could materially impact the effective tax rate, income tax expense, anticipated tax benefits, deferred tax assets, cash flows, and profitability.
• Inability to fully realize expected tax benefits corresponding to payments made under the Unit Exchange and Tax Receivable Acceleration Agreements.
• Provisions in the company's certificate of incorporation and bylaws and Delaware law that may discourage or prevent strategic transactions, including a takeover.
• Impact of stockholder activism, takeover proposals, proxy contests, or short sellers on the company's stock price and reputation.
• Risks related to current and future indebtedness, including the existing credit facility, and the ability to obtain additional financing on favorable terms.
• Fluctuations in quarterly operating results and the trading price and volume of Class A common stock.
• Failure to maintain an effective system of internal controls over financial reporting or inability to remediate any identified weaknesses.
• Impact on the price of Class A common stock if dividends are ceased or reduced from current levels.
• Potential dilutive issuances of common stock, preferred stock, limited partnership units, or debt securities.

Future Outlook

The company expects continued material increases in average revenue share obligations to members, particularly as GPO participation agreements extended in 2020 are renewed, with the majority anticipated in fiscal year 2026. Remaining Contigo Health businesses are expected to be substantially transitioned to partners or wound down by December 31, 2025. Management anticipates ongoing challenges from inflation, rising input costs (including labor), and higher interest rates, but believes these trends will ultimately increase demand for its Supply Chain Services and Performance Services solutions in cost management, quality and safety, and value-based care over the long-term. Information technology, especially AI, is expected to continue playing a key enabling role in workflow efficiency, cost reduction, performance improvement, and care delivery transformation. The Informatics and Technology Services (ITS) reporting unit faces a heightened risk of future impairments if underlying assumptions or market factors change unfavorably. The company anticipates quarterly dividends to continue to be paid in the third month of each fiscal quarter and expects cash generated from operations and Credit Facility borrowings to provide adequate liquidity for anticipated capital expenditures, business growth, and debt service requirements.

Management Comments

• "We continue to monitor tariff developments and are working to continue to build resiliency within our portfolio and diversification of suppliers to mitigate the financial impact on our members and other customers."
• "We believe that we have continued to limit the impact of inflation on our members and believe that we maintain lower inflation impacts across our diverse product portfolio than national levels."
• "We are continuously working to manage price increases as market conditions change."
• "We expect that these remaining businesses [Contigo's] will be substantially, if not entirely, transitioned to partners or wound down by December 31, 2025."
• "We expect to address the majority of these remaining member agreements [GPO participation agreements] in fiscal year 2026."
• "We believe that we have adequate capital resources at our disposal to fund currently anticipated capital expenditures, business growth and expansion, and current and projected debt service requirements."

Industry Context

The U.S. healthcare industry is a significant component of the economy, with expenditures projected to grow by 5.8% annually from 2024-2033, reaching 20.3% of GDP by 2033. Hospitals are a major part of this spending, with supply chain expenses representing a material portion of their budgets. The industry is experiencing intense pressure from reimbursement rate changes, a shift from fee-for-service to value-based payment models, and a strong focus on cost containment and quality improvement. This environment drives demand for sophisticated business intelligence, expanded data sets, and technology solutions, including increasing reliance on artificial intelligence. The industry is highly regulated, with ongoing scrutiny from federal and state authorities, including changes to the Affordable Care Act and increased enforcement of fraud, waste, and abuse laws. Antitrust oversight of Group Purchasing Organizations (GPOs) is also evolving, with the DOJ and FTC withdrawing prior guidance, indicating a more case-by-case enforcement approach. The market for healthcare products and services is fragmented, highly competitive, and characterized by rapidly evolving technology and product standards.

Comparison to Industry Standards

• The company's ASCENDrive Performance Group has enabled members to identify over $1.4 billion in additional savings compared to their U.S. hospital peers not participating in the program since its inception in 2009.
• The SURPASS Performance Group has identified over $433.9 million in additional savings for its members through efforts in more than 130 categories since its inception in 2018.
• The digital invoicing and payables automation business aims to become a leading digital invoicing and payables platform for all of healthcare, agnostic of ERP, GPO, or treasury partner.
• The company's technology and services platform leverages what it believes to be the nation's leading comprehensive database, representing over 20 years of data from more than 1,000 hospitals.
• The company believes that improvements to the healthcare supply chain are needed to bring it on par with other industries that have more sophisticated supply chain management.
• Competitors include other large traditional healthcare GPOs such as HealthTrust Purchasing Group (a subsidiary of HCA Holdings, Inc.), Managed Health Care Associates, Inc., and Vizient, Inc.
• In the supply chain co-management business, the company competes with organizations like The Resource Group and CPS Solutions, LLC.
• For procure-to-pay services, competitors include Global Healthcare Exchange, LLC (GHX), Coupa Software Inc., Taulia, and tier one treasury banks (e.g., JPMorgan Chase and Co., Wells Fargo, Bank of America, etc.).
• In Performance Services, competitors range from niche companies to large entities like Veradigm, Inc., Epic Systems Corporation, Health Catalyst, Inc., IBM Corporation, Oracle Corporation, Deloitte Consulting, Optum, Inc. (a subsidiary of UnitedHealth Group, Inc.), and Kaufman, Hall and Associates, LLC (a subsidiary of Vizient, Inc.).

Management Changes

Corporate Governance

Legal Proceedings

• The company is periodically involved in litigation, including claims related to contractual disputes, product liability, tort or personal injury, employment, antitrust, intellectual property, and regulatory matters.
• Past class action antitrust lawsuits by suppliers or purchasers of medical products, alleging conspiracy, have been successfully resolved.
• A shareholder derivative complaint, 'City of Warren General Employees Retirement System v. Michael Alkire, et al.', filed on March 4, 2022, was settled in June 2024.
• No current material litigation is believed to be ongoing as of the filing date.
• The company is subject to ongoing state and federal tax examinations, including an IRS examination for the tax year ended June 30, 2023.

Related Party Transactions

• The company's GPO members, in many cases, are significant equity owners of the company, implying a related party relationship.
• The company owned approximately 26% of PRAM Holdings, LLC (a consolidated subsidiary holding an investment in Prestige Ameritech, Ltd.), with the remaining interests held by 16 member health systems or their affiliates.
• The company owned approximately 15% of ExPre Holdings, LLC (a consolidated subsidiary holding an investment in Exela Holdings, Inc.), with the remaining interests held by 11 member health systems or their affiliates.
• Net income attributable to non-controlling interests of $10.6 million for FY2025 was recognized for non-Premier ownership in consolidated subsidiaries, including 74% and 85% interests held by member health systems or their affiliates in PRAM and ExPre, respectively.
• The company has a joint venture with certain members and DeRoyal Industries for medical gown production, with minimum funding commitments contingent on member gown purchases.
• Notes payable to former limited partners (member-owners) related to the August 2020 Restructuring were fully paid in fiscal year 2025, representing a past related party financial obligation.

Stakeholder Impact

• Shareholders: Experienced a significant decline in stock value (from $100 to $74.48 since June 30, 2020), reduced net income and Adjusted EBITDA, and a net working capital deficit. Share repurchases were executed, and quarterly dividends of $0.21 per share continue.
• Employees: Subject to strategic initiatives and restructuring, which included severance expenses. The company emphasizes competitive compensation, benefits, well-being, and development programs.
• Customers (Healthcare Providers/Members): Face potential higher procurement costs due to tariffs and increased fee share obligations. Their demand for the company's services is influenced by third-party payer reimbursement changes and the broader economic environment. The company aims to provide cost savings and quality improvements.
• Suppliers: May be adversely affected by tariffs, impacting their pricing structures and operational capabilities. The company is working to build supply chain resiliency and diversification to mitigate these impacts.
• Creditors: The company has $280.0 million in outstanding borrowings under its Credit Facility and a net working capital deficit, which could impact its ability to obtain additional financing on favorable terms.

Next Steps

• Address the majority of remaining GPO member agreements (representing approximately 20% of gross administrative fees extended in 2020) in fiscal year 2026.
• Substantially transition or wind down remaining Contigo Health businesses by December 31, 2025.
• Continue to monitor tariff developments and build resiliency within the portfolio and diversification of suppliers to mitigate financial impact on members and customers.
• Continuously work to manage price increases as market conditions change.
• Continue to invest in and develop AI technologies and incorporate them into products and services.
• The Board of Directors will continue to declare quarterly cash dividends.
• The company will need to refinance or replace its Credit Facility at or before its maturity date of December 12, 2027.
• The Internal Revenue Service (IRS) will be examining the tax year ended June 30, 2023.

Key Dates

Recommendation

The company's financial performance for fiscal year 2025 shows significant deterioration, with substantial declines in net revenue, net income, and Adjusted EBITDA. The recognition of a large goodwill impairment charge for a key reporting unit (ITS) indicates underlying business challenges and potential overvaluation. The shift to a net working capital deficit and increased interest expense further strain the balance sheet. While strategic divestitures and share repurchases were undertaken, they did not offset the overall negative financial trends. The competitive landscape, ongoing pressure to increase GPO member fee shares, and regulatory uncertainties (e.g., Medicaid expenditure reductions, evolving AI regulation) present significant headwinds. Given these factors, a seasoned investor would likely consider selling to mitigate further downside risk and reallocate capital to more promising opportunities.

Keywords

Healthcare Technology, Group Purchasing Organization, Supply Chain Management, Clinical Analytics, Value-Based Care, SaaS, Health IT, Hospital Services, Medical Supplies, Corporate Governance, SEC Filing, Financial Performance, Risk Management, Share Repurchase, Divestiture, Acquisition, Impairment, Cybersecurity, Artificial Intelligence, PINC